Leigh syndrome is the most common pediatric presentation of mitochondrial disease. This neurodegenerative disorder is genetically heterogeneous, and to date pathogenic mutations in >75 genes have been identified, encoded by 2 genomes (mitochondrial and nuclear). More than one-third of these disease genes have been characterized in the past 5 years alone, reflecting the significant advances made in understanding its etiological basis. We review the diverse biochemical and genetic etiology of Leigh syndrome and associated clinical, neuroradiological, and metabolic features that can provide clues for diagnosis. We discuss the emergence of genotype-phenotype correlations, insights gleaned into the molecular basis of disease, and available therapeutic options.
D
isorders of mitochondrial energy generation are the most frequent group of inherited metabolic disorders, with an estimated incidence of at least 1 in 5,000 live births. 1 The most common clinical presentation of mitochondrial disease in children is a progressive neurodegenerative disorder known as Leigh syndrome (LS; Mendelian Inheritance in Man [MIM] 25600). LS has an estimated prevalence of 1 per 40,000 live births 2 ; however, much higher incidences have been observed in specific populations owing to founder mutations. 3, 4 Since the identification of the first pathogenic mutation in an LS patient in 1991, 5 >75 disease genes have been identified, highlighting the remarkable heterogeneity underlying this disorder. Nearly 30 of these LS disease genes have been characterized in the past 5 years alone, reflecting how the introduction and greater utility of massively parallel sequencing (MPS) technology has transformed our ability to identify the genetic basis of disease. Beyond the identification of novel disease genes, MPS has also facilitated the identification of patients with mutations in known disease genes, enabling the emergence of genotypephenotype relationships for this rare disorder. Advances in characterizing the genetic basis of LS have consolidated our understanding of the molecular basis of disease, revealing a diverse biochemical etiology consistent with the annotation of LS as a disorder of energy generation.
Neurological decline in LS patients is associated with the development of bilateral symmetrical lesions within the brainstem and basal ganglia structures, which characterize the disease. 13, 15, 16 These lesions are observed as regions of focal hyperintensity on T2-weighted magnetic resonance imaging (MRI), and elevated lactate may be detected by magnetic resonance spectroscopy. Additional neuroradiological abnormalities such as white matter involvement and cerebral atrophy may also be observed. 17 In 1996, we defined criteria for a stringent diagnosis of LS, requiring that characteristic neuropathology or neuroradiology must be accompanied by progressive neurodegeneration with (1) clinical evidence of brainstem and/or basal ganglia dysfunction, (2) intellectual and motor developmental delay, and (3) elevated serum or cerebrospinal fluid (CSF) lactate indicating abnormal energy metabolism. 2 In 2015, it would seem prudent to amend criterion (3) to "abnormal energy metabolism indicated by a severe defect in oxidative phosphorylation (OXPHOS) or pyruvate dehydrogenase complex (PDHc) activity, a molecular diagnosis in a gene related to mitochondrial energy generation, or elevated serum or CSF lactate." Where patients do not fulfill these stringent criteria, a diagnosis of Leigh-like syndrome can be considered, particularly in patients with atypical neuroradiology or normal lactate levels. 2 
The Development of Our Understanding of the Etiological Basis of LS
Since Denis Leigh's first description of LS in 1951, 18 there have been several key research milestones that have contributed to our understanding of the etiological basis of LS (Fig 1) . The similarity of the neuropathology to Wernicke encephalopathy, a condition of thiamine deficiency, and findings of elevated blood lactate and pyruvate suggested that a metabolic abnormality was the underlying disease etiology. 19, 20 Before the first genetic mutation was identified in 1991, 5 40 years of clinical and biochemical investigation provided evidence that deficiency of the PDHc, and of nicotinamide adenine dinucleotide (NADH):ubiquinone oxidoreductase (complex I) and cytochrome c oxidase (complex IV) within the OXPHOS pathway, could cause LS. [21] [22] [23] Together with the finding of abnormal mitochondrial morphology in skeletal muscle tissue from patients, these abnormalities suggested a common theme of defective mitochondrial energy metabolism. 22 Subsequently LS was reannotated as a mitochondrial encephalopathy.
It has since been established that multiple other enzymatic deficiencies can underlie LS, mostly linked directly to OXPHOS or broader pathways of energy generation. The OXPHOS pathway of electron transfer, proton transport, and adenosine triphosphate (ATP) synthesis comprises 5 multiprotein complexes located in the mitochondrial inner membrane (Fig 2) . Biochemical defects in each of the 5 OXPHOS complexes, and the electron carrier coenzyme Q 10 (CoQ 10 ), have been observed in LS patients. PDHc enables the generation of electron donors for OXPHOS; hence PDHc deficiency also represents a disorder of energy generation. Complex I deficiency is the most common biochemical cause of LS, with nearly one-third of all LS disease genes associated with complex I deficiency. Isolated complex IV deficiency and multiple OXPHOS defects are also frequently observed, whereas defects of complexes II, III, or V or of CoQ 10 are relatively rare. 2, 6, 7 Measurement of OXPHOS and PDHc enzymes in a patient biopsy or cell line is often undertaken to provide evidence of a biochemical defect in these pathways to support a clinical diagnosis of LS.
The Heterogeneous Genetic Basis of LS
To date, pathogenic mutations in >75 genes have been identified in affected patients (Table 1, and see Supplementary Table for more detailed information). Most of these disease genes encode structural components of the OXPHOS complexes, or proteins required for their assembly, stability, and activity. As is the case for other mitochondrial diseases, there are several possible modes of inheritance including maternal (for mutations in mitochondrial DNA [mtDNA]) and autosomal recessive or X-linked (for nuclear-encoded genes). Despite the remarkable number of established disease genes, many LS patients remain without a genetic diagnosis, indicating that there are still more disease genes to be identified.
The aim of this article is not to provide an indepth review of all known forms of LS and Leigh-like syndrome, but rather to discuss the most relevant biochemical and genetic etiologies, associated clinical and biochemical features relevant for diagnosis, and therapeutic options (where available, summarized in Table 2 ). We focus on the more common nuclear-encoded genetic causes, as well as describing types of LS and Leigh-like syndrome caused by mtDNA mutations.
Complex I Deficiency
The most frequent clinical presentation of complex I deficiency is LS, 24 and complex I deficiency is the leading biochemical basis of LS. 2, 6, 7 Mutations in the NADH dehydrogenase (ubiquinone) Fe-sulfur protein 4 (NDUFS4) subunit are the most frequent autosomal recessive cause of complex I-associated LS, with > 20 cases reported. 24 Interestingly, almost all patients reported with NDUFS4 mutations had LS, in contrast to mutations in other nuclear-encoded complex I subunits, which may be associated with heterogeneous phenotypes. Patients with NDUFS4 mutations display a characteristic LS presentation, experiencing onset and demise typically within the first 8 months of life and no later than 30 months. Neuroradiological features in these infants included bilateral symmetrical basal ganglia lesions in almost all cases, often extending down to the cerebral peduncles, pons, and medulla, and frequently with associated cerebral atrophy. 24, 25 Approximately one-third of all reported cases also had hypertrophic cardiomyopathy. Mutations in NADH dehydrogenase (ubiquinone) flavoprotein 1 (NDUFV1) and NDUFS1 have also been widely reported to cause LS. NDUFS1 mutations appear to be associated with an early age of death, with all reported patients presenting by 8.5 months and succumbing by 4 years. 24 Most patients with NDUFV1
mutations also died in early childhood, although a few cases were alive in late childhood. 26, 27 Thus, NDUFS4-, NDUFV1-, and NDUFS1-mediated LS appear to be particularly severe forms of the disease. Whereas all reported NDUFS4 mutations except 1 predict complete loss-offunction alleles, no patients have been described with 2 null alleles of NDUFV1 or NDUFS1, suggesting that complete loss of these 2 proteins may be incompatible with life.
Complex II, Complex III, and CoQ 10 deficiencies
Deficiencies of complex II, complex III, or CoQ 10 (ubiquinone) are rare causes of LS, and collectively underlie <10% of all cases. 2, 6, 7, 28 Mutations in the complex II subunit SDHA were the first nuclear mutations identified to cause OXPHOS disease. 29 Some patients with SDHA mutations have a severe infantile presentation of LS with rapid demise, 29 but other patients may experience a mild LS course, with survival into late childhood years, preservation of cognitive abilities, and an "almost normal 
Biochemical Deficiency Genes
Pyruvate dehydrogenase PDHA1, a PDHB, PDHX, DLAT, DLD, LIPT1, LIAS, TPK1, SLC19A3, SLC25A19
Coenzyme Q 10 PDSS2
Complex III UQCRQ, BCS1L, TTC19
Disease genes that cause secondary impairment of mitochondrial energy generation school life." 28, 30 Nearly all patients with mutations in the complex III assembly factor TTC19 develop neuroimaging abnormalities consistent with LS. 31 Occasional patients with LS and CoQ 10 deficiency have been reported. 9, 32 Prompt recognition of this subgroup of LS is imperative, because these patients may respond to CoQ 10 supplementation and survive into adulthood, 32 although this has not been consistently observed. 33 One report described improvement of hepatic but not neurological symptoms, 34 and another patient with CoQ 10 -deficient LS due to PDSS2 mutations did not respond to treatment. 9 
Complex IV Deficiency
Complex IV deficiency underlies 15% of LS cases. 2, 6, 7 Mutations in SURF1, encoding a complex IV assembly factor, are the most common cause of complex IV deficient LS and are among the most frequently reported causes of LS, with >200 cases described to date in the literature. 35 Our recent natural history study of a SURF1 patient cohort highlighted the relatively homogenous clinical and biochemical presentation associated with SURF1 deficiency. 35 However, a minority of patients with SURF1 mutations lack the neuroradiological hallmarks of LS or show atypical features such as leukodystrophy and atrophy. 35, 36 Survival analysis of 142 SURF1
patients revealed a median age of death at 5.4 years, 35 indicating longer survival in SURF1-associated LS than is observed for LS patients due to mutations in other complex IV disease genes SCO2, LRPPRC, and ETHE1.
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LRPPRC mutations were originally reported in an isolated French-Canadian population. 37, 40 Characteristic clinical features associated with French-Canadian LS (LSFC; MIM 220111) include mild facial dysmorphism, liver pathology, and a clinical course punctuated by episodes of acute metabolic decompensation that contribute significantly to mortality. 3, 37 Fifty-five of 56 reported cases inherited homozygous LRPPRC p.A354V mutations, 37 reflecting a founder effect that has resulted in an incidence of LSFC of 1 in 2,000 live births (Table 3) . 3 Broader effects of LRPPRC dysfunction on mitochondrial post-transcriptional and translation processes have recently been recognized, including deficiency of ATP synthase. 41 Despite presenting as an isolated complex IV deficiency, the pathogenesis of LRPPRC mutations may therefore be attributable to a global defect of mitochondrial translation. Mutations in ETHE1 cause ethylmalonic encephalopathy (EE; MIM 602473), a presentation that resembles LS clinically and neuroradiologically. 38, 42 The characterization of a role for ETHE1 in sulfide detoxification revealed EE as a manifestation of sulfide toxicity, whereby the associated isolated complex IV deficiency is a consequence of sulfide accumulation. 43 Accordingly, therapeutic strategies that reduce sulfide accumulation resulted in clinical, biochemical, and neuroradiological improvement in patients with ETHE1 mutations. 44 The only complex IV subunit with mutations causing LS is the recently reassigned subunit NDUFA4, which was previously thought to be a subunit of complex I. NDUFA4 mutations have been reported to cause childhood onset LS with prominent epilepsy, learning difficulties, and survival into adulthood. 45 Combined OXPHOS Deficiencies Because mtDNA encodes structural components of complexes I, III, IV, and V, a molecular defect that impairs mtDNA replication or translation can cause combined OXPHOS deficiency. Thus, mutations in various disease genes associated with mtDNA depletion or defective translation have been identified in patients with LS (see Table 1, see Supplementary Table, A for more detailed information). The predominant causes of LS associated with mtDNA depletion are mutations in SUCLA2 or SUCLG1, encoding subunits of succinyl-CoA synthetase, which catalyzes the conversion of succinyl-CoA to succinate within the citric acid cycle. Methylmalonic aciduria is frequently observed in these patients due to an accumulation of succinyl-CoA, and can be used to screen for patients with mutations in SUCLG1 and SUCLA2 manifest similarly, they can be differentiated by liver involvement (SUCLG1) or deafness (more common with SUCLA2 mutations). 49 The SUCLA2 c.534 1 1G>A mutation has a high carrier frequency in the Faroe Islands owing to a founder effect, with an estimated LS incidence of 1 in 1,700 in that population (see Table  3 ). 4 An interaction between succinyl-CoA synthetase and nucleoside diphosphate kinase, an enzyme involved in regulating mitochondrial nucleotide supply, has been hypothesized to account for mtDNA depletion in patients with SUCLA2 and SUCLG1 mutations. 46 Nuclear encoded mt-tRNA modifying enzymes are required for efficient mitochondrial translation, and mutations in these proteins represent a relatively new class of LS disease genes. Mitochondrial methionyl-tRNA formyltransferase (MTFMT) was the first LS disease gene of this type to be reported. MTFMT mutations were initially identified in 2 unrelated LS patients through targeted exome sequencing of the MitoExome, 50 and subsequently identified in multiple other LS patients. 51 Most cases carry at least 1 copy of the c.626C>T mutation, which has a carrier frequency of 1 in 100 in the European population and so may account for a significant proportion of LS within this population. Cohort studies have suggested that mtDNA mutations underlie approximately 10 to 20% of LS cases. 2, 6, 7 To date, mutations in 13 of the 37 mtDNA-encoded genes have been described to cause LS, with the majority in genes encoding subunits of complex I or V, or in mitochondrial tRNAs (see Table 1, and Supplementary Table, A for more detailed information). LS can also be caused by large-scale mtDNA deletions. 2 The percentage of mtDNA molecules that carry the pathogenic mutation, known as the level of heteroplasmy, is an important determinant of the clinical presentation. As a severe manifestation of mitochondrial disease, LS is typically associated with high mutant loads of 90%, although MTND5 mutations associated with complex I deficiency are notable for their propensity to cause LS even when the mutant load is <50% in tissues including brain, where patients have been observed to survive into adulthood. [52] [53] [54] Mutations in complex I subunits MTND3 and MTND5, and in the complex V subunit MTATP6, are the most frequent mtDNA causes of LS. MTATP6 mutations represent the only established genetic basis of complex V-mediated LS, and mutations in this gene are estimated to underlie 10% of all LS cases. 2, 6, 7, 55 The majority of these patients carry either the MTATP6 m.8993T>G or the less severe m.8993T>C mutation, which were among the first LS mutations described. 56, 57 Although uncommon, mutations in 5 mt-tRNAs have been identified in LS patients, including the well-known m.3243A>G MTTL1 mutation that is more commonly associated with the syndromes of mitochondrial encephalopathy with lactic acidosis and strokelike episodes (MELAS) and maternally inherited diabetes and deafness, and the m.8344A>G in MTTK that typically causes myoclonic epilepsy with ragged red fibers.
58,59
Although mtDNA is inherited maternally, many patients with mtDNA mutations lack any maternal family history suggesting mtDNA disease. This can be because the heteroplasmic mutant load in other family members is below the pathogenic threshold for that mutation. De novo mutations in mtDNA are also relatively common, so a mutation present at high levels of heteroplasmy in the proband can be undetectable in the mother and other maternal relatives.
60,61

Pyruvate Dehydrogenase Complex Deficiency
Evidence of elevated pyruvate and a lactate:pyruvate ratio of < 20 can indicate PDHc deficiency in LS patients, with agenesis of the corpus callosum another common finding. 62 Mutations in PDHA1, encoding the E1 alpha subunit, are the predominant cause of PDHc-associated LS. 62, 63 PDHA1 is an X-chromosome gene, but approximately equal numbers of boys and girls are diagnosed with PDHA1 mutations. 62 This pseudodominant inheritance is not surprising given that random X-inactivation means that typically 50% of cells will express the mutant allele. Skewed X-inactivation means that the biochemical diagnosis of PDHc deficiency in females can be challenging. 64 Cohort studies of PDHc-deficient individuals support previous observations that PDHA1 likely has a high de novo mutation rate. 62, 63 Mutations in genes related to the PDHc cofactors lipoic acid and thiamine pyrophosphate (TPP) have more recently been described to cause LS. The LIPT1 and LIAS genes encode enzymes responsible for synthesis and transfer of the lipoic acid cofactor, and the DLD gene encodes the PDHc subunit E3 dihydrolipoamide dehydrogenase. Patients with PDHc deficiency due to mutations in these genes present with a recognizable metabolic profile that reflects additional deficiency of aketoglutarate dehydrogenase and branched-chain a-keto acid dehydrogenase. [65] [66] [67] PDHc deficiency due to mutations in genes associated with TPP availability (TPK1, SLC19A3, and SLC25A19) can be missed because of the presence of TPP in routine PDHc enzymatic assays, but may be identifiable when measuring PDHc activity in the absence of TPP. 68, 69 Mutations in the thiamine transporter SLC19A3 are well known to cause biotin/thiamineresponsive basal ganglia disease (BTBGD; MIM 607483), which phenocopies LS as a progressive encephalopathy with similar neuroimaging and episodic decline. 70 Unlike typical LS, patients with BTBGD can show significant clinical and neuroradiological improvement following administration of thiamine and high-dose biotin, particularly when commenced early in the disease course. 71 Patients with SLC19A3 mutations have been described as having "treatable" or "reversible" LS.
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Disease Genes Associated with Leigh-like Syndrome 76, 77 Disease genes that predominantly underlie a Leigh-like presentation that may not fit a stringent LS diagnosis also include SERAC1, which causes 3-methylglutaconic aciduria with deafness, encephalopathy, and Leigh-like syndrome associated with isolated or combined OXPHOS enzyme deficiency. 78 These patients often present with atypical neuroradiology, or with unusual additional symptoms including abnormal behavior.
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The Emergence of Genotype-Phenotype Relationships
Historically, strong correlations between a molecular defect and clinical features could not be identified among LS patients, 2 in part reflecting the low numbers of patients for most disease genes. However, the increasing utilization of MPS technology has facilitated the identification of multiple LS patients with mutations in the same gene, enabling the recognition of emerging genotype-phenotype correlations (see Table 3 for examples). The presence of these signature features in combination with a biochemical deficiency and knowledge of the patient's ethnicity may suggest a specific genetic basis. Beyond having characteristic symptoms, different LS disease genes can underlie distinct disease courses, where differences in median age of onset, and length of disease course, can be observed (illustrated in Fig 3) . For example, NDUFS4 mutations appear to be associated with early onset and death, whereas patients with mutations in SUCLA2 or the complex IV assembly factor PET100 experience early onset but a more variable lifespan including survival into adolescence. The accumulation of additional patients with an established genetic basis of disease and thorough phenotyping may reveal more LS genotype-phenotype correlations. More research is required to determine the molecular basis of such relationships, although they may be expected to in part reflect tissue-specific effects relating to expression levels, function, and/or responses to the genetic defect. Being able to recognize the genetic or biochemical basis of disease has important utility for guiding treatment options, and in some cases can enable lifesaving intervention for the genetic forms that are most responsive to treatment such as SLC19A3 or BTD mutations (outlined in Table 2 ).
Established Molecular Defects Indicate a Common Disorder of Energy Generation
Our current understanding of the genetic basis of LS supports impairment in mitochondrial energy generation being the key to pathogenesis. However, it appears that the specific enzyme or process that is disrupted is not as relevant to molecular pathogenesis, given the remarkably diverse range of molecular defects causing LS. These include defects of catalytic activity, stability, or assembly of individual OXPHOS complexes, of mtDNA maintenance and expression, and of PDHc activity and cofactors required for enzyme activity (see Table 1 , and Supplementary Table, A for more detailed information).
The identification of several disease genes that are not known to encode proteins with a direct role in OXPHOS or PDHc activity raises new questions about the pathogenesis of LS (see Table 1 , and Supplementary Table, B for more detailed information). Some of these defects appear to cause secondary defects of PDHc or OXPHOS enzymes, which may show variability across patients and tissues. 78, [80] [81] [82] Such secondary defects have not been reported in patients with biotinidase deficiency due to BTD mutations, a treatable condition that can manifest as LS (see Table 2 ), 83, 84 although there is evidence of ATP deficiency and complex IV inhibition from animal and cellular models. 85, 86 Mutations in the phospholipid remodeling protein SERAC1 and apoptosis-inducing factor AIFM1 may impair OXPHOS by reducing the stability of the mitochondrial membrane. 78, 82 However, the mechanism by which mutations in enzymes involved in valine catabolism (ECHS1, HIBCH) and biotin recycling (BTD) impair OXPHOS and PDHc activity remains to be determined. These enzymes facilitate pathways that can produce substrates for the citric acid cycle, 81, 87 an important source of electrons for OXPHOS. However, the relevance of this to pathogenesis is unclear, as is the contribution of primary effects of these disorders such as perturbed valine catabolism. 80, 81 Instead, an accumulation of toxic reactive metabolites has been suggested to be the mechanism by which ECHS1 and HIBCH mutations impair OXPHOS and PDHc activity, 81,88 similar to the toxic accumulation of sulfide due to ETHE1 mutations described above. 43 Although it may not be the primary consequence of mutation, an indirect effect on mitochondrial energy generation can therefore be sufficient to cause the development of LS. Our understanding of cerebral energy metabolism further supports the central role of a diminished energy supply to the pathogenesis of LS. Brain metabolism accounts for 20 to 25% of resting energy expenditure in adults. 89 The metabolic requirements of the brain increase during infancy and peak in early childhood, where it uses glucose at a rate of up to 66% of the body's resting metabolism. 90 Therefore, it is not surprising that defects in OXPHOS and energy generation can cause early onset neurodegeneration in the form of LS. Studies indicating that the brain's metabolic requirements are highest at 5 years of age 90 are relevant to observations suggesting that survival past periods of increased vulnerability in infancy and early childhood may predict a lifespan into and beyond late childhood for patients with LS. This is supported by the cohort study of LRPPRC FIGURE 3: Genotype-phenotype correlations with respect to disease course. Box and whisker plot representation of the ages of onset, death, or last report for patients with mutations in NDUFS4, NDUFV1 (complex I deficiency), SURF1, PET100 (complex IV deficiency), SUCLA2, and MTFMT (combined oxidative phosphorylation deficiency) as reported in the literature. Genotype-phenotype differences in disease course can be observed between the genetic and biochemical forms of disease. Data points are represented as error bars depicting minimum and maximum, the box edges depicting the 1st and 3rd quartiles, with the line within the box representing the median. Number of patients for whom information was available: NDUFS4, 21; NDUFV1, 12; SURF1, 21; PET100, 10; SUCLA2, 31; MTFMT, 12.
patients, where no metabolic crises were observed in patients after the age of 7 years, 37 and suggested by the notably later median age at last report relative to the median age of death observed across patients with either PET100, NDUFV1, or MTFMT mutations in Figure 3 . The particular vulnerability of the basal ganglia and brainstem structures to neurodegeneration in LS patients is unexplained. Positron emission tomography studies examining the cerebral metabolic rate for glucose in infants and children suggested that the brainstem and basal ganglia/thalamus do not necessarily have the highest energy requirement of all examined brain structures in conditions of basal metabolism. 91 Furthermore, the capacity for patients with inherited mitochondrial energy generation disorders to develop neuropathological abnormalities distinct from LS, including in infancy and early childhood, 92 suggests that other factors beyond a reduced energy supply must contribute to pathogenesis. Previous studies demonstrating differences in mitochondrial protein expression across mouse tissues, including between different brain regions, 93 imply that cell-and tissuespecific responses to a molecular defect of mitochondrial energy generation will also contribute to pathogenesis. This is supported by transcriptomic studies of cells and tissues from mitochondrial disease patients demonstrating tissue-specific patterns of transcriptional dysregulation. 94 
Updating Diagnostic Strategies to Incorporate New Knowledge of Molecular Etiologies
Detailed approaches to diagnosis of LS have been published elsewhere. 19, 55 The initial steps remain a detailed medical and family history, physical examination including determining extent of multiorgan involvement, measurement of laboratory parameters such as lactic acid in blood and CSF, and imaging (MRI and magnetic resonance spectroscopy). 19 In patients such as those described in Table 3 , the phenotype may prompt investigation of a specific gene, such as SURF1 in a child with hypertrichosis and relative cognitive sparing. 35 However, in most patients the next step has traditionally been to measure OXPHOS and PDHc enzyme activities in a muscle biopsy and cultured skin fibroblasts, respectively, the results of which can guide subsequent gene-by-gene analysis. Although enzyme testing may often still be required for diagnosis, the diagnostic paradigm is increasingly shifting to using MPS first, to potentially avoid the need for muscle biopsy. Testing gene panels of perhaps a few hundred genes is a popular approach, although the rate of discovery of novel disease genes means that such panels can become outdated quite quickly. Whole exome sequencing can potentially detect mutations in any nuclear gene but typically is not a sensitive test for mtDNA mutations, so it may need to be accompanied by a separate test for mtDNA mutations. Whole genome sequencing can detect mutations in nuclear and mtDNA genes, but is less widely available than exome sequencing. Each of these approaches has specific advantages and disadvantages, 95, 96 but in our experience they can enable molecular diagnosis of LS in >60% of patients with a stringent LS diagnosis, as defined by the original criteria of Rahman et al. 2 
Insights into Broader Cellular Dysfunction: An Emerging Area for Therapeutic Intervention
There is a growing body of evidence supporting the contribution of broader cellular dysfunction in disorders of mitochondrial energy generation. Recent studies have demonstrated that PDHc and OXPHOS defects can induce transcriptional dysregulation of multiple cellular pathways including those that regulate RNA and protein metabolism. 94 These disturbances in cellular metabolism appear to be primarily mediated by effects on pathways responsible for sensing and responding to nutrient availability, including effects on the expression and activity of regulator of cellular growth mTORC1. 94 Treatment with rapamycin, an inhibitor of mTORC1, improved lifespan and attenuated neurodegeneration in the Ndufs4 knockout mouse model of LS, 97 supporting the notion that dysregulation of these pathways contributes to pathogenesis. More recently, improvement in mitochondrial cristae morphology was observed to modestly but significantly improve motor performance, lifespan, and complex I activity in Ndufs4 knockout mice, 98 suggesting that effects on mitochondrial morphology may additionally contribute to disease pathology. Molecular defects of PDHc and OXPHOS may furthermore impair normal cell function through mechanisms distinct from energy generation per se. PDHc and OXPHOS enzyme defects can produce a cellular environment more conducive for the production of reactive oxygen species (ROS). Increased ROS have been observed in cellular models of PDHc and OXPHOS enzyme deficiencies, 99, 100 and there is evidence of increased oxidative damage to proteins in affected brain regions of the Ndufs4 knockout mice. 101 However, these results have been inconsistent, 102, 103 and increases in ROS production do not always correlate with neurodegeneration.
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A possible alternative explanation could be that elevated ROS production is simply reflecting a highly reduced state of the respiratory chain. This typically leads to a partial block in NADH oxidation, with a concomitant decrease in the NAD 1 /NADH ratio. 105 This redox imbalance may lead to dysregulation of the signaling pathways related to nutrient sensing referred to earlier. 94 Alleviation of oxidative stress has therefore emerged as a promising avenue of therapy for LS and other mitochondrial diseases, including the development of antioxidants EPI-743 and RP103, which are currently being examined in clinical trials. 109 Increased ROS are also implicated in the activation of inflammatory pathways that may in turn alter mitochondrial function and produce a state of chronic stress that further compromises cellular function. 110, 111 The contribution of oxidative stress to disease pathogenesis may therefore be multifaceted. Another relevant consequence of the molecular defects observed to cause LS is elevation of lactate. 2 Increased lactate levels reflect a greater utilization of glycolysis for energy generation, and may contribute to lesion development in LS patients, including through alterations of pH when lactic acidosis ensues. 16 An observed correlation between CSF lactate levels and disease severity in LS patients 6 supports the pathological significance of lactate. Interestingly, attenuation of lesion development and neurological decline in Ndufs4 knockout mice following rapamycin treatment was suggested to in part reflect a reduction in toxic glycolytic metabolites within the brain. 97 Significantly, this study also demonstrated that neurological improvement and an increase in lifespan could be achieved independently of an effect on the primary defect in complex I assembly. This supports the role of broader cellular dysfunction in disease pathogenesis, and the validity of targeting these pathways therapeutically. Characterization of the precise molecular mechanisms driving disease pathology could therefore have great utility for the development of new therapies.
Conclusion
Like other mitochondrial diseases, there is currently no effective treatment for LS as a group. 112 However, there are several genetic and biochemical forms of LS that can benefit from therapeutic intervention, emphasizing the importance of determining the molecular basis of disease in LS patients. Furthermore, confirmation of the genetic basis of disease enables access to accurate genetic counseling and assisted reproductive technologies. MPS has transformed the approach for determining the genetic basis of LS, and therefore has the potential to markedly improve diagnostic and clinical outcomes for patients. Consolidating our understanding of the cellular mechanisms underlying disease pathology is important for enabling the development of novel therapeutics.
